The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases by Sethupathy, Praveen
PATHOGENESIS OF TYPE 2 DIABETES AND INSULIN RESISTANCE (RM WATANABE, SECTION EDITOR)
The Promise and Challenge of Therapeutic MicroRNA Silencing
in Diabetes and Metabolic Diseases
Praveen Sethupathy1,2
Published online: 25 April 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract MicroRNAs (miRNAs) are small, non-coding,
RNA molecules that regulate gene expression. They have a
long evolutionary history and are found in plants, viruses, and
animals. Although initially discovered in 1993 in
Caenorhabditis elegans, they were not appreciated as wide-
spread and abundant gene regulators until the early 2000s.
Studies in the last decade have found that miRNAs confer
phenotypic robustness in the face of environmental perturba-
tion, may serve as diagnostic and prognostic indicators of
disease, underlie the pathobiology of a wide array of complex
disorders, and represent compelling therapeutic targets. Pre-
clinical studies in animal models have demonstrated that phar-
macologic manipulation of miRNAs, mostly in the liver, can
modulate metabolic phenotypes and even reverse the course
of insulin resistance and diabetes. There is cautious optimism
in the field about miRNA-based therapies for diabetes, several
of which are already in various stages of clinical trials. This
review will highlight both the promise and the most pressing
challenges of therapeutic miRNA silencing in diabetes and
related conditions.
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Introduction
Recent advances in sequencing technology have unveiled the
diversity and complexity of both small and long non-coding
RNAs (ncRNAs). Small RNAs, including short interfering
RNAs (siRNAs) and microRNAs (miRNAs), mediate post-
transcriptional gene silencing by RNA interference (RNAi),
which was designated as the BBreakthrough of the Year^ by the
journal Science in 2002 and was the discovery for which the
Nobel Prize in Physiology or Medicine was awarded in 2006.
Furthermore, also in 2006, two specific miRNAs were selected
as BMolecule of the Year^ by the International Society for
Molecular and Cell Biology and Biotechnology Protocols and
Researchers (ISMCBBPR) based on the discovery that their
tissue expression levels can accurately predict lung cancer prog-
nosis. Since then, miRNAs have emerged as candidate circulat-
ing biomarkers of physiologic status [1]; potent regulators of
diverse biological pathways from differentiation [2] to energy
metabolism [3]; adaptive responders to environmental stimuli
such as dietary nutrients [4], microbes [5], and pollutants [6];
inter-organ messengers in health and disease [7•]; and potential
therapeutic targets in a wide array of disorders [8]. One context
in which the role of miRNAs is increasingly appreciated is type
2 diabetes (T2D) [9], as well as related metabolic conditions
such as obesity and hyperlipidemia.
The discovery of the importance ofmiRNAs to the etiology
of these diseases was greatly facilitated by the advent of anti-
sense technology for the study of miRNAs in vivo [10]. Anti-
miRNA oligonucleotides (AMOs), also referred to as
antagomiRs, are chemically modified stretches of nucleic
acids that are partially or wholly complementary to specific
target miRNAs. AMOs bind their target miRNAs with high
specificity and potently suppress their molecular functions. In
order to be effective in vivo, AMOs must be stable in circula-
tion and readily taken up by tissues, which are features that are
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conferred by several different types of chemical modifications.
The different AMO chemistries have been summarized previ-
ously [11]. One popular modification is the locked nucleic acid
(LNA), wherein one or more monomers along the length of an
AMO are locked in a specific conformation that enhances base
stacking and increases the stability of base pairing with its target
miRNA by 2–8 °C per locked monomer. The locked confor-
mation is also refractory to digestion by exo- and endo-nucle-
ases, thereby increasing the stability of AMOs in circulation.
AMOs are increasingly used for in vivo research studies of
miRNA function and are being developed for potential thera-
peutic use as well [12]. For example, LNA-mediated inhibition
of miR-122 (initially tested in non-human primate models [13])
in patients with chronic hepatitis C was shown in phase 2a
clinical trials to be non-immunogenic and highly effective at
reversing the course of the disease by promoting viral clearance
[14]. The success of LNA-anti-miR-122 (miravirsen) has gen-
erated sustained interest in the use of AMOs for in vivo silenc-
ing of additional miRNAs in other health conditions, most no-
tably cancers and metabolic diseases.
Promising Pre-clinical Examples of Therapeutic
MicroRNA Silencing in Metabolic Disease
Numerous studies in the last few years have used AMOs for
therapeutic silencing of at least ten different miRNAs in ani-
mal models to study their roles in diabetes, as well as related
conditions including obesity, hyperlipidemia, and insulin re-
sistance, and their potential as therapeutic targets (Table 1).
Below are highlighted specific examples in obesity/T2D,
as well as hyperlipidemia.
Obesity and Type 2 Diabetes
Obesity and T2D are complex metabolic disorders that affect
hundreds of millions of people worldwide, have no cure, and
are associated with numerous debilitating co-morbidities. At
the physiologic level, T2D is characterized by resistance to
insulin action in peripheral tissues such as the liver, adipose,
and muscle and/or failure of pancreatic beta cells to produce/
secrete enough insulin to meet metabolic demands, resulting
in chronically elevated blood glucose levels (hyperglycemia)
and numerous downstream complications. Both obesity and
T2D are growing epidemics and critically require new and
effective preventative and therapeutic strategies.
In 2011, Trajkovski et al. [18••] published a seminal study
on therapeutic silencing of miRNAs in a mouse model of
obesity/T2D. Specifically, they administered 2′-O-methyl
modified AMOs by tail-vein injection to silence both miR-
103 and miR-107 in the livers and adipose of ob/ob mice as
well as wild-type C57BL/6J mice on high-fat diet (HFD) for
12 weeks. The effects of the AMO on miR-103/107 levels in
other tissues were not reported. They found in both animal
models that AMO-mediated suppression of miR-103 and
miR-107, which are elevated in the livers of rodents and
humans with insulin resistance, significantly alleviate hyper-
glycemia in large part by promoting insulin signaling in the
liver and adipose. Specifically, while glucose uptake by mus-
cle was not affected, glucose production and glycogen content
in the liver, as well as adipocyte size, were significantly re-
duced. Overall, the findings from this study revealed that both
miR-103 and miR-107 are key negative regulators of insulin
signaling and also suggested that they are novel candidate
therapeutic targets for T2D. More recent studies have shown
that miR-107 levels may be regulated by inflammatory cues
[26] in addition to dietary lipids [27] and that miR-107 is
involved in the control of circadian rhythm [27], indicating
that both miR-103 and miR-107 likely have broader roles in
T2D etiology than through regulation of insulin signaling
alone. In April 2015, Regulus Therapeutics announced that a
GalNAc-conjugated AMO against miR-103/107 (RG-125)
was selected by AstraZeneca for clinical development for
the treatment of hepatic steatosis in patients with T2D and/or
Table 1 Pre-clinical animal
studies of anti-miRNA
oligonucleotide (AMO) based
therapeutics in diabetes and
related metabolic conditions
MicroRNA Metabolic phenotype/disease References
let-7 Type 2 diabetes Frost and Olson, PNAS [15]
miR-34 Obesity/type 2 diabetes Fu et al., PNAS [16]
Choi et al., Aging Cell [17]
miR-103/107 Obesity/type 2 diabetes Trajkovski et al., Nature [18••]
miR-802 Obesity/type 2 diabetes Kornfeld et al., Nature [19]
miR-208a Obesity/type 2 diabetes Grueter et al., Cell [20]
miR-181a Insulin resistance/type 2 diabetes Zhou et al., Diabetologia [21]
miR-379 Obesity/hyperlipidemia deGuia et al., EMBO Journal [22]
miR-146b Obesity Ahn et al., EMBO Molecular Medicine [23]
miR-24 Steatosis/hyperlipidemia Ng et al., Hepatology [24]
miR-29 Hyperlipidemia Kurtz et al., Scientific Reports [25]
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insulin resistance (http://ir.regulusrx.com/releasedetail.cfm?
ReleaseID=905305).
In 2013, Choi et al. [17] used 2′-O-methoxyethyl
phosphorothioate-modified AMOs to silence expression and
activity of miR-34a (AMO34) in a mouse model of obesity
(8–12-week-old C57BL6/J mice fed HFD for 20 weeks).
AMO34a treatment was carried out by tail-vein injection three
times over a 12-day period. Hepatic miR-34a levels, which
were aberrantly elevated in the chronic HFD-fed mice before
dosing, were rescued to levels seen in gender- and age-
matched lean mice after the full course of AMO34a treatment.
The effects of AMO34a on miR-34a levels in other tissues
were not reported. Notably, AMO34a treatment led to signif-
icant improvements in glucose tolerance and insulin sensitiv-
ity, matching levels observed in lean mice. Furthermore, si-
lencing of miR-34a also significantly reduced serum levels of
IL-6, insulin, and triglycerides, although levels of alanine
transaminase (ALT) and aspartate transaminase (AST) were
unaffected. These findings indicate that AMO34a treatment
can correct the metabolic imbalance induced by chronic
HFD without side effects of liver inflammation or other tox-
icities. A subsequent study in 2014 from the same group
showed that suppression of miR-34a in adipose tissue reduces
adiposity and improves metabolic phenotypes in diet-induced
obese mice by promoting beige and brown fat formation [28];
however, these experiments were conducted with lentiviral
inhibition constructs since AMOs are not as efficiently taken
up by adipose compared to the liver.
Also in 2013, Kornfeld et al. [19] showed that miR-802 is
significantly increased in the liver of two different mouse
models of obesity and insulin resistance: (1) 8–12-week-old
mice homozygous for a diabetes mutation in the leptin recep-
tor gene (db/db) and (2) 8–12-week-old mice fed HFD. They
also demonstrated that hepatic miR-802 levels are significant-
ly correlated with body mass index (BMI) in human subjects.
These findings suggest that miR-802 may be linked to the
development of systemic insulin resistance. Kornfeld et al.
intravenously delivered small LNAs against miR-802 to
HFD-fed mice on two consecutive days. Two weeks after
the final dose, the authors observed remarkable suppression
of miR-802 in the liver and kidney, but not in any other tissue.
The inhibition of miR-802 led to a significant improvement in
glucose tolerance, and this effect was not mediated by in-
creased glucose uptake by the skeletal muscle or white adi-
pose tissue, but rather enhanced insulin sensitivity in the liver
(as measured by hepatic glucose production). miR-802 is rel-
atively new on the miRNA scene, and much more remains to
be uncovered about its functions in the liver as well as in other
tissues where it is robustly expressed. For example, the effects
of LNA-mediated suppression of miR-802 in the kidney have
not yet been investigated. However, there is reason for cau-
tious optimism regarding miR-802 as a compelling therapeu-
tic target for obesity and insulin resistance.
Hyperlipidemia and Type 2 Diabetes
Hyperlipidemia refers to the chronic elevation of lipids (cho-
lesterol and fat) in the bloodstream, which is a significant risk
factor for a variety of metabolic diseases, including T2D. The
condition is most commonlymanaged bymodification of diet,
as well as drugs such as statins and fibrates. However, these
medications are not uniformly effective across individuals in
the human population, and in some cases, long-term and/or
high-dose usage could even lead to very harmful side effects
such as severe muscle damage [29], which may not be curable
if not detected and treated sufficiently early. Therefore, there
remains a critical need for new, safe, and effective medications
to combat hyperlipidemia. Anti-gene inhibitors are already in
various stages of clinical testing for hyperlipidemia. For ex-
ample, treatment with an anti-sense oligonucleotide inhibitor
of the gene apolipoprotein C-III (APOC3), a critical regulator
of plasma triglyceride levels, led to safe, dose-dependent, and
long-term reductions in plasma triglycerides in phase II clin-
ical trials [30].
In a recent study, Kurtz et al. [25] administered LNAs by
tail-vein injection in 8-week-old wild-type C57BL6/J mice to
inhibit miR-29 family members (LNA29) in vivo. One week
post-dosing, the LNAs were most effectively taken up by the
liver and kidney, and as in previous studies, the LNAs did not
successfully cross the blood–brain barrier. Treatment with the
LNA29 significantly reduced plasma triglyceride levels by
∼15 % and cholesterol levels by ∼40 %, which is commensu-
rate with the effects of statins, themost widely prescribed class
of medications for hypercholesterolemia. The authors further
demonstrated that the striking phenotypic effects of LNA29
were due in large part to suppression of lipogenic pathways in
the liver. These findings raise the possibility that LNA29
could be used to lower cholesterol levels in diet-based or ge-
netic animal models of hypercholesterolemia. Importantly,
miR-29 has also been implicated in the control of insulin sig-
naling [31], and therefore, inhibition of miR-29 may improve
hepatic or even systemic insulin sensitivity as well, though
this has not yet been demonstrated. Indeed, hepatic miR-29
is significantly elevated in a rat genetic model of diabetes and
restored to normal levels upon treatment with Pioglitazone
[32]. However, it should also be noted that miR-29 has also
been shown to regulate a variety of other biological processes,
including fibrosis [33, 34], immune response [35], and cell
proliferation [36]. Therefore, future studies will need to assess
comprehensively the systemic influences of AMO-mediated
suppression of miR-29 and whether any potential side effects
can be mitigated or circumvented with alternate dosing
schemes or cocktail therapies.
In another study, Ng et al. [24] injected LNAs against miR-
24 (LNA24) weekly for 4 weeks into 16-week-old wild-type
C57BL6/J mice that were fed a HFD for 8 weeks. After com-
pletion of the dosing scheme, miR-24 levels were dramatically
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reduced in the liver, although the efficacy of inhibition in other
tissues was not reported. While the LNA24 treatment had no
effect on the overall body or liver weight, it significantly re-
duced fat accumulation in both the liver and the plasma of the
HFD-fed mice. The authors further demonstrated that the ef-
fect of LNA24 was mediated by increased expression and
activity of the insulin induced gene 1 (Insig1) protein, which
is responsible for sequestering in the endoplasmic reticulum
the key transcription factor responsible for lipid production in
the liver, sterol regulatory element binding protein 1 (Srebp1)
[37]. Therefore, silencing of miR-24, as in the case of silenc-
ing of miR-29, leads to the suppression of hepatic lipogenesis,
suggesting that LNA24 may be a therapeutic strategy for met-
abolic conditions in which lipid levels are pathologic.
Recently, miR-24 was also identified as a critical regulator
of pancreatic beta cell function [38], in part through direct
regulation ofHnf1a and Neurod1, which underlie the etiology
of maturity-onset diabetes of the young (MODY).
Furthermore, it was shown that suppression of aberrantly ele-
vated miR-24 in pancreatic islets from HFD-fed mice signif-
icantly improves glucose-stimulated insulin secretion. These
findings suggest that miR-24-based therapies may be relevant
for T2D as well. Further studies are required to evaluate the
effects of long-term dosing with LNA24, as well as to assess
the efficacy of treatment in more severe metabolic disease
models (e.g., long-term HFD).
Other Conditions of Metabolic Dysfunction
Some cardio-metabolic diseases quite different from T2D still
share some features of metabolic dysfunction. One such disor-
der of growing public health concern is atherosclerosis, which
is characterized by the buildup of arterial plaque (cholesterol,
triglycerides, calcium, and other cellular debris) that causes the
hardening and constriction of arteries, leading to vascular dis-
ease, coronary heart disease, stroke, and death. It is the most
prevalent disease in the developed world and is predicted to be
the number one cause of death worldwide by the year 2020.
Some medications, including those that lower plasma total cho-
lesterol levels and improve lipoprotein profiles, can be used for
treatment. However, the development of new, complementary
therapeutic approaches for the regression of atherosclerosis re-
mains an open and important area of biomedical investigation.
The first and best-studied miRNA in the context of atheroscle-
rosis is miR-33, which has two isoforms, miR-33a and miR-
33b, encoded within the genes sterol regulatory element bind-
ing factor 2 (Srebf2) and sterol regulatory element binding fac-
tor 1 (Srebf1), respectively. The proteins encoded by these two
genes are master transcriptional regulators of cholesterol and
fatty acid synthesis [37]. In 2010, several independent studies
used AMOs against miR-33 (AMO33) in mice to establish an
important functional role for miR-33 in the maintenance of
systemic cholesterol homeostasis [39–41]. Follow-up studies
in mouse models of atherosclerosis (e.g., Ldlr−/−) produced
conflicting reports about the safety and efficacy of long-term
treatment [42, 43]. However, in vivo studies in non-human
primates appear to suggest that therapeutic silencing of miR-
33 is safe and atheroprotective, both in the short and long term
[44, 45]. The latter findings indicate that AMO33 could remain
a candidate therapeutic strategy for atherosclerosis.
Key Challenges in Therapeutic MicroRNA Silencing
Despite the exciting and rapid pace of advance in the devel-
opment and pre-clinical use of potent miRNA silencing tech-
nologies, there remain several major challenges for clinical
development, three of which I will highlight here.
(1) The effects of long-term (>5 weeks) AMO-mediated si-
lencing of miRNAs are simply not known in most cases
and require more thorough investigation. One notable
exception is miR-33. While short-term (<5 weeks) si-
lencing of miR-33 in mice was shown to be highly safe
and efficacious by multiple groups, the data for long-
term silencing has been conflicting. Although studies
demonstrated that long-term silencing of miR-33 is safe
in non-human primates, the mouse results provide cau-
tion enough to researchers that the effects of prolonged
AMO treatment must be evaluated rigorously and com-
prehensively before proceeding to clinical trials.
(2) The use of larger animal models for pre-clinical studies is
critical but still limited. While rodent-based models are
among the most widely used, larger animals such as pigs
and monkeys are more physiologically relevant from a
therapeutic standpoint. Also, the extent to which rodent
miRNA networks are conserved in humans is still an
open question, and it is important to consider pre-
clinical studies in animals that are less evolutionarily
distant from humans. Rodent models are incredibly valu-
able, in part because of the availability of rich resources,
and they will remain an important part of the fabric of
translational science. However, it will be important to
develop more resources for studies of larger animal
models in order to gain confidence in the relevance of a
particular AMO for potential clinical trials.
(3) AMO-based therapeutic silencing of miRNAs is currently
heavily biased toward the liver (Table 1), in large part
because the liver (as well as the kidney) is most effective
at taking up circulating AMOs. While liver miRNAs con-
tribute considerably to the governance of metabolic phe-
notypes, miRNAs in other tissues likely also have critical
roles in the development of metabolic disease, such as
miR-200a, which regulates pancreatic beta cell survival
in type 2 diabetes [46•]; miR-375, whichmodulates insulin
secretion from beta cells [47] and maintains alpha/beta cell
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mass in pancreatic islets [48]; and miR-7a, which controls
the physiologic adaptation of beta cells to the metabolic
conditions of obesity and type 2 diabetes [49]. Pancreatic
islets and most other metabolic tissues such as adipose and
skeletal muscle do not efficiently take up the type of
AMOs currently in use. Alternate strategies are clearly
needed in order to perform therapeutic silencing of
miRNAs in tissues other than the liver and kidney.
Conclusions and Future Outlook of Therapeutic
MicroRNA Silencing
A few different approaches have been suggested in the literature
to expand therapeutic silencing of miRNAs beyond the liver.
One strategy in particular holds substantial promise: aptamer-
AMO chimeras [50, 51••]. Specifically, an AMO can be chem-
ically linked to an RNA aptamer, which is a structured RNA
molecule designed to have high-affinity binding to a cell-
surface receptor that is specific to a particular cell type. Once
the aptamer-AMO chimera binds to the target receptor and is
internalized, the link between the aptamer and the AMO is sev-
ered by Dicer, releasing the AMO in the cytoplasm. In this ap-
proach, the RNA aptamer essentially serves as a Bguide^ for the
AMO to specific cell types. RNA aptamers can be selected for
specific receptors of interest by high-throughput screening of
large RNA libraries using strategies such as Systematic
Evolution of Ligands by Exponential Enrichment (SELEX)
[52]. Aptamer-siRNA chimeras have already been used effec-
tively in xenografted mice to target particular oncogenes for
knockdown only in cancer cells (using an aptamer designed for
EpCAM, a cell surface antigen that is highly expressed in most
epithelial cancers) in order to suppress tumor growth [53]. CD4
aptamer-siRNAchimeras have also been used to inhibit the trans-
mission of human immunodeficiency virus (HIV) in humanized
mice [54]. Aptamer-AMO chimeras represent the next frontier
for cell-type specific therapeutic silencing of miRNAs in meta-
bolic disorders, as well as a wider array of diseases.
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